Skip to content
Call organization(855) 958-4663
Non-clinical specialist

Momchilo Vuyisich, PhD

Founding CSO & Head of Clinical Research, Viome · ViomeRNA metatranscriptomics, Microbiome science, Clinical research, Diagnostic platform development

Viome founding CSO who developed the Los Alamos RNA metatranscriptomics platform behind its testing line

Portrait of Momo Vuyisich, PhD

Practice

About

Momo Vuyisich, PhD is Viome's Founding Chief Science Officer and Head of Clinical Research, and one of the scientists behind the company's core RNA metatranscriptomic platform. He earned his PhD from the University of Utah in RNA biochemistry, then spent more than a decade at Los Alamos National Laboratory developing the technology Viome commercialized. His publication record includes Viome's salivary metatranscriptome cancer-detection work and population-scale metatranscriptomic platform validation.

Approach

Signature approach

Vuyisich's scientific frame is RNA gene expression as a live readout of biology. At Viome, that means reading active signals from bacteria, viruses, fungi, archaea, and human cells across stool, saliva, and blood, then using the same metatranscriptomic pipeline for wellness reports and CancerDetect.

What sets them apart

  • Platform originator. The metatranscriptomics technology Viome commercialized was developed through his Los Alamos work before company launch.
  • Published Viome science. His Scholar profile includes the salivary metatranscriptome cancer-detection papers and population-scale metatranscriptomics validation work.
  • RNA-first career. His PhD work centered on RNA biochemistry, giving Viome's platform a long scientific through-line.

Focus

Specialties

GI & Gut HealthCancer Prevention & Screening

Training

Education

  • PhD, Chemistry / RNA biochemistry
    University of Utah (Beal Lab) (2002)
  • BS, Microbiology
    University of Texas at El Paso (1997)

Published work

Elsewhere

Collaboration

  • Naveen Jain
    Viome co-founder & CEO — serial entrepreneur (Moon Express, Intelius, Infospace) who funded the LANL-to-Viome platform commercialization
  • Guruduth Banavar, PhD
    Viome co-founder & Founding CTO — former IBM Research VP and Watson AI lead; co-leads clinical research with Vuyisich and is first author on Viome's salivary metatranscriptome cancer-detection papers

Profiles

Verification

Profile updated

Primary sourcehttps://www.viome.com/company

Where a detail is missing, it means we have not verified it—not that the answer is no. Directory listings are for informational purposes only. Inclusion does not constitute endorsement. Verify credentials and qualifications independently.